Tremfya (also known by its generic name guselkumab) is a biologic medication that was approved by the FDA in July 2017 for the treatment of moderate-to-severe plaque psoriasis in adults. In July 2020, the FDA also approved Tremfya to treat adults with active psoriatic arthritis. Tremfya was approved in September 2025 to treat children 6 years and older, weighing at least 40 kg, who live with moderate to severe plaque psoriasis, are candidates for systemic therapy or phototherapy, or live with active psoriatic arthritis (PsA).
Tremfya is given by injection under the skin at week 0 (the first week of treatment) and week 4, and then every 8 weeks afterwards.
To learn more, please visit the Tremfya website.
